老年人中的AML - - 当少可能是更多的时候
Eric S Winer1, Richard M Stone2
1Dana-Farber Cancer Center, 450 Brookline Ave, Boston, MA, 02215, USA. erics_winer@dfci.harvard.edu.
Current oncology reports
|October 17, 2024
概括
患有急性髓性白血病 (AML) 的老年人可以从个性化治疗策略中受益. 新型向疗法提供了较少毒性和更有效的选择,改善了这个患者群体的治疗结果.
科学领域:
- 血液学 血液学 血液学
- 老年医学 老年医学
- 在瘤学瘤学.
背景情况:
- 急性髓性白血病 (AML) 在老年患者中提出了独特的挑战.
- 对老年AML患者的治疗决定需要仔细考虑其特定的生物学和临床特征.
研究的目的:
- 评估老年人AML独特的生物和临床特征.
- 突出治疗前评估对老年AML患者个性化护理的重要性.
- 讨论从密集治疗到非密集治疗的不断变化的治疗环境.
主要方法:
- 对老年患者评估和基因数据进行预测性治疗指导的审查.
- 对最近获得FDA批准的AML向治疗方法的分析.
- 新型疗法与老年人常规化疗的比较.
主要成果:
- 老年和遗传数据显著有助于选择AML的治疗方法.
- 九种新的向疗法,主要是小分子抑制剂,已被批准用于AML.
- 老年AML患者现在可以接受具有相似或更高效率的毒性较小的治疗方法.
- TP53突变AML仍然是一个挑战,但新的药物提供了未来的希望.
结论:
- 对老年AML患者来说,个性化治疗方法至关重要.
- 新型向疗法代表了显著的进步,提供了更好的结果和降低了毒性.
- 目前正在进行的新药研发有望为老年AML患者带来进一步的改善.
相关概念视频
Alzheimer's Disease: Treatment
166
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
166
Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Aging
37
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
37
Factors Affecting Drug Response: Overview
1.9K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.9K
Cognitive Development During Adulthood
65
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
65
Heart Failure V: Medical Management
2
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
2


